Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability

Background. Advanced HCC is a clinical challenge with limited treatment options. The multikinase inhibitor sorafenib is the first and only agent showing a survival benefit in these patients. In this study we evaluate the efficacy and tolerability of sorafenib in an unselected patient population. Fur...

Descripción completa

Detalles Bibliográficos
Autores principales: Køstner, Anne Helene, Sorensen, Morten, Olesen, René Krøjgaard, Grønbæk, Henning, Lassen, Ulrik, Ladekarl, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569916/
https://www.ncbi.nlm.nih.gov/pubmed/23431262
http://dx.doi.org/10.1155/2013/931972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569916/
https://www.ncbi.nlm.nih.gov/pubmed/23431262
http://dx.doi.org/10.1155/2013/931972

Ejemplares similares